Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Firastotug · ADG-116

Monoclonal antibody · Antagonist of CTLA-4 · developed by Adagene

Phase 1 Most advanced trial (none active)
ADAG Developer
1 Registered trials

What is Firastotug?

Firastotug is a human monoclonal antibody that binds CTLA-4 on T cells and blocks its inhibitory signaling, enhancing cytotoxic T-lymphocyte-mediated immune responses against cancer cells. It is being studied in advanced and metastatic solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ADG-116
Drug type
Monoclonal antibody
Targets
CTLA-4
Mechanism
Antagonist of CTLA-4
Pathways
T-cell activation, immune checkpoint inhibition
Therapy area
Oncology
Developer
Adagene Inc (ADAG)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
8B1J60R28A

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04501276 Phase 1 Advanced/Metastatic Solid Tumors Completed ADAG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced/Metastatic Solid Tumors

Other drugs acting on CTLA4

More from Adagene

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ADAG page.

Follow ADAG, the company behind Firastotug

See ADAG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ADAG catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.